OncoMatch/Clinical Trials/NCT04787289
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
Is NCT04787289 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Bevacizumab for ovarian cancer.
Treatment: Bevacizumab — A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Higher doses of anti-cancer based drugs are not always better than lower doses and can cause more side effects without improvement of cancer. These patients will be randomly assigned either 7.5 mg/kg or 15mg/kg of bevacizumab combined with chemotherapy . Comparing these two doses will determine if the lower dose-level is non-inferior, and could lead to practice changes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
all patients must have received at least one prior regimen of chemotherapy including platinum
Cannot have received: anti-angiogenesis inhibitor (bevacizumab)
Patients must have never received an anti-angiogenesis inhibitor including bevacizumab
Lab requirements
Blood counts
Neutrophils less than 1 x 10^9 /L [excluded]
Neutrophils less than 1 x 10^9 /L [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify